CLDX Stock Summary and Trading Ideas (Celldex Therapeutics | NASDAQ:CLDX)

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics trades on the NASDAQ stock market under the symbol CLDX.

As of April 18, 2024, CLDX stock price declined to $38.53 with 530,375 million shares trading.

CLDX has a beta of 1.71, meaning it tends to be more sensitive to market movements. CLDX has a correlation of 0.11 to the broad based SPY ETF.

CLDX has a market cap of $2.53 billion. This is considered a Mid Cap stock.

Last quarter Celldex Therapeutics reported $4 million in Revenue and -$.83 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.09.

In the last 3 years, CLDX stock traded as high as $57.20 and as low as $19.85.

The top ETF exchange traded funds that CLDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

CLDX has underperformed the market in the last year with a return of +12.1%, while the SPY ETF gained +22.2%. In the last 3 month period, CLDX fell short of the market, returning -2.8%, while SPY returned +5.2%. However, in the most recent 2 weeks CLDX has outperformed the stock market by returning -2.6%, while SPY returned -2.6%.

CLDX support price is $38.55 and resistance is $40.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDX stock will trade within this expected range on the day.